Introduction
Transrectal ultrasound-guided prostate biopsy, universally abbreviated as TRUS-guided prostate biopsy, is a well-established, minimally invasive diagnostic procedure in which systematic tissue cores are obtained from the prostate gland under real-time ultrasound visualization to evaluate for the presence of prostatic malignancy or other histopathological abnormalities. It remains the definitive tissue-acquisition procedure in the diagnostic pathway of prostate cancer and constitutes one of the most frequently performed urological and interventional procedures worldwide, reflecting the substantial global prevalence of prostate cancer as the most commonly diagnosed non-cutaneous malignancy in men across many populations.
The procedure bridges a critical diagnostic gap between clinical suspicion, generated by an elevated or rising serum prostate-specific antigen level or an abnormal digital rectal examination, and histopathological confirmation, which alone provides the tissue diagnosis necessary to guide oncological management. Despite the significant evolution of prostate cancer diagnostics — including the increasing clinical integration of multiparametric magnetic resonance imaging and the emergence of MRI-targeted fusion biopsy techniques — the TRUS-guided systematic biopsy approach retains its central role in the diagnostic algorithm, whether employed independently or in combination with targeted sampling strategies.
The clinical importance of accurate prostate biopsy extends beyond mere cancer detection. It provides essential information regarding tumor grade through the Gleason scoring system and its contemporary derivative, the International Society of Urological Pathology grade group classification, as well as tumor extent, bilaterality, and perineural invasion — parameters that collectively inform treatment decisions spanning active surveillance, radical prostatectomy, radiotherapy, focal therapy, and systemic treatment. In this context, procedural accuracy, adequate tissue sampling, and rigorous patient preparation are not merely technical imperatives but direct determinants of the oncological outcomes that follow.
Understanding Prostate Anatomy, Zonal Architecture, and Malignant Pathology
The prostate gland is a fibromuscular and glandular organ of the male genitourinary system situated immediately inferior to the urinary bladder, anterosuperior to the rectum, and encircling the proximal urethra at the bladder neck. In the adult male it weighs approximately twenty to thirty grams in the absence of benign or malignant enlargement, though considerable variation exists with advancing age as benign prostatic hyperplasia progressively increases glandular volume. The gland is enclosed within a fibrous pseudocapsule and is invested posteriorly by Denonvilliers’ fascia, which separates it from the anterior rectal wall — an anatomical relationship that makes the transrectal approach to biopsy both anatomically logical and technically accessible.
The internal architecture of the prostate is most accurately conceptualized according to the zonal anatomy described by McNeal, which divides the gland into four distinct zones carrying different functional and pathological significance. The peripheral zone constitutes the largest anatomical division, comprising approximately seventy percent of the glandular tissue of the normal prostate, and is situated posterolaterally — forming the bulk of the gland palpable on digital rectal examination and directly accessible through the rectal wall on transrectal ultrasound. It is within the peripheral zone that the overwhelming majority of prostatic adenocarcinomas — approximately seventy to eighty percent — arise, explaining why the posterior and posterolateral aspects of the gland are the primary targets of systematic biopsy sampling protocols.
The transition zone, situated bilaterally around the proximal urethra, is the predominant site of benign prostatic hyperplasia, the progressive nodular glandular and stromal proliferation that accounts for lower urinary tract symptoms in aging men. Although transition zone carcinomas constitute a smaller proportion of prostatic malignancies, they tend to be detected at more advanced volumes given their relatively protected anterior and central location, inaccessible to standard posterior-directed biopsy templates. The central zone surrounds the ejaculatory ducts and is relatively resistant to malignant transformation, while the anterior fibromuscular stroma constitutes a non-glandular zone devoid of acinar tissue and therefore not a primary target for systematic biopsy.
Prostatic adenocarcinoma arises from the secretory epithelial cells lining the prostatic acini and ducts, characterized histopathologically by glandular architectural disarray, nuclear enlargement, prominent nucleoli, and absence of the basal cell layer present in benign glands. The Gleason grading system assigns scores from one to five based on the dominant glandular architectural pattern, and the combined Gleason score — summing the primary and secondary patterns — provides the cornerstone of histological risk stratification. Contemporary reporting uses the ISUP grade group system, which consolidates Gleason scores into five clinically meaningful prognostic categories directly linked to biochemical recurrence, metastatic risk, and cancer-specific mortality.
Prostatic intraepithelial neoplasia of high grade and atypical small acinar proliferation are additional histopathological entities that may be identified on biopsy and carry specific clinical implications requiring surveillance and, in certain contexts, repeat biopsy. The recognition of these pre-malignant or indeterminate lesions on initial biopsy is an additional dimension of diagnostic information that TRUS-guided sampling provides, influencing subsequent monitoring and re-evaluation strategies.
Indications for the Procedure
TRUS-guided prostate biopsy is indicated across a range of clinical scenarios that collectively define the population at elevated risk for clinically significant prostatic malignancy. The most prevalent indication is an elevated serum prostate-specific antigen level above the age-adjusted reference range, or a PSA level within the reference range that is demonstrating a concerning rate of rise over serial measurements — a pattern referred to as PSA velocity — or an abnormally elevated proportion of free to total PSA ratio suggesting increased malignant risk.
An abnormality detected on digital rectal examination — including asymmetrical firmness, an indurated nodule, or obliteration of the normal glandular contours — constitutes a clinical indication for biopsy regardless of the absolute PSA level, as digital rectal examination abnormalities carry independent predictive value for malignancy. In the contemporary diagnostic pathway, suspicious lesions identified on multiparametric magnetic resonance imaging of the prostate — classified according to the Prostate Imaging Reporting and Data System as PI-RADS category three, four, or five — are an increasingly important driver of biopsy referral, whether proceeding to TRUS-guided systematic sampling, cognitive fusion biopsy, or software-based MRI-ultrasound fusion targeted biopsy.
Repeat biopsy following a prior negative result is indicated when PSA continues to rise, when PSA density — defined as PSA corrected for prostate volume — remains disproportionately elevated, when a suspicious MRI lesion was not adequately sampled at initial biopsy, or when high-grade prostatic intraepithelial neoplasia or atypical small acinar proliferation was identified on the prior histological specimen. In the setting of known prostate cancer under active surveillance protocols, scheduled repeat biopsy at defined intervals provides ongoing histological reassessment to detect grade progression that would trigger transition to active treatment. Evaluation of the prostate following radiation therapy, when biochemical recurrence is suspected, may also constitute an indication for tissue sampling to guide salvage treatment planning.
Pre-Procedure Preparation
Pre-procedure preparation for TRUS-guided prostate biopsy is structured to minimize the two principal procedural risks — infection and hemorrhage — while optimizing patient comfort and ensuring accurate tissue acquisition. A thorough clinical assessment identifies patient-specific risk factors including anticoagulant or antiplatelet medication use, prior adverse reactions to local anesthetics, history of anorectal pathology that might preclude or complicate transrectal probe insertion, prior abdominal or pelvic surgery, and a history of previous prostate biopsies with documentation of any infective complications.
Antibiotic prophylaxis is the single most critical component of pre-procedure preparation, given that the transrectal approach necessarily traverses the non-sterile rectal mucosa to access the prostate and carries a well-recognized risk of infectious complications including urinary tract infection, prostatitis, and potentially life-threatening septicemia. Fluoroquinolone antibiotics, historically the cornerstone of prophylactic regimens, have been subject to increasing scrutiny due to the rising global prevalence of fluoroquinolone-resistant Enterobacteriaceae — particularly Escherichia coli — within rectal flora, directly linked to the surge in post-biopsy sepsis rates observed over the past decade. Contemporary prophylaxis strategies have evolved accordingly, with many centers adopting targeted prophylaxis based on pre-biopsy rectal swab culture and sensitivity testing to identify patients harboring resistant organisms and tailoring antibiotic choice accordingly. Augmented regimens incorporating intravenous aminoglycosides such as gentamicin, fosfomycin, or cephalosporins with broadened gram-negative coverage are employed in patients identified as carrying fluoroquinolone-resistant organisms or as belonging to high-risk groups.
Bowel preparation, typically administered the evening before the procedure in the form of a rectal enema, reduces the luminal fecal content of the rectum, improving ultrasound image quality by minimizing acoustic interference and reducing the bacterial load at the point of needle transgression. While practice varies between institutions and the evidence base for enema use on infectious outcome is not uniformly conclusive, it remains standard practice in the majority of centers performing TRUS-guided biopsy. Anticoagulant and antiplatelet medications are reviewed and withheld according to established bridging protocols, with the specific cessation interval determined by the agent, the patient’s thromboembolic risk, and the clinical urgency of the procedure.
Patients are counseled comprehensively regarding the procedural technique, expected sensations of pressure and transient sharp discomfort during needle firing, the expected number of biopsy cores, the possibility of post-procedural hematuria, hematospermia, and rectal bleeding, the signs and symptoms of infective complications requiring urgent medical attention, and the timeline for histopathological results. Informed written consent is obtained after this discussion. Review of any available multiparametric MRI imaging is conducted prior to the procedure to identify specific targets for additional directed sampling to be incorporated into the systematic protocol.
How the Procedure is Performed
TRUS-guided prostate biopsy is performed in an outpatient procedural setting and does not require general anesthesia in the majority of patients. The patient is positioned in the left lateral decubitus position with the knees drawn toward the chest, though the lithotomy position may be employed depending on operator preference and institutional practice. The rectal region is cleaned, and an initial digital rectal examination is performed to assess the consistency of the prostate, identify any gross abnormalities, and confirm the absence of anorectal pathology that would preclude probe insertion.
A dedicated biplanar or end-firing transrectal ultrasound probe — operating at frequencies between six and ten megahertz to provide optimal near-field resolution of the prostatic architecture — is introduced gently into the rectum with the application of coupling gel. The probe is advanced to the level of the seminal vesicles, identified as paired hypoechoic tubular structures superior to the prostate base, and systematically withdrawn to survey the entire prostate in both axial and sagittal planes. The prostate volume is calculated using the prolate ellipsoid formula, and the glandular architecture, echotexture, capsular integrity, and any focal hypoechoic lesions — which represent the most common sonographic correlate of peripheral zone carcinoma, though with recognized low specificity — are systematically documented. The relationship of the prostate to surrounding structures including the neurovascular bundles, bladder neck, and rectal wall is assessed.
Periprostatic nerve block is administered prior to needle sampling to provide adequate procedural analgesia. Under real-time ultrasound guidance, a 22-gauge spinal needle introduced through the biopsy guide channel of the transrectal probe is directed to the junction of the seminal vesicle and prostate base at the periprostatic fat plane on each side — the site of the neurovascular bundle entry into the prostate — and one to five milliliters of local anesthetic, typically one percent lidocaine or a mixture of lidocaine and bupivacaine, is deposited bilaterally. Additional infiltration at the prostatic apex and at the mid-gland level on each side may be performed to extend the zone of analgesia. A period of two to three minutes is allowed for the anesthetic to take effect before biopsy sampling commences.
Systematic biopsy is performed using an 18-gauge spring-loaded automated biopsy needle introduced through a needle guide attached to the transrectal probe, directed in real time under continuous ultrasound visualization to predetermined anatomical targets within the prostatic parenchyma. The extended twelve-core systematic template — the contemporary standard, having superseded the earlier sextant protocol — distributes biopsy cores across six anatomical zones on each side of the prostate: the base, mid-gland, and apex bilaterally, with each bilateral zone sampled at both the medial and lateral extent to adequately represent the peripheral zone. Each core measures approximately seventeen millimeters in length and provides a cylindrical tissue sample sufficient for histopathological assessment.
The needle is positioned under ultrasound guidance with the needle tip visualized at the target site, and the patient is warned of the imminent firing of the spring-loaded mechanism before each core is obtained. The biopsy gun is activated, advancing the inner cutting stylet and outer cutting cannula in rapid sequence to obtain the tissue core, which is then carefully expressed into individually labeled formalin-filled specimen containers identified by anatomical location. This systematic labeling allows direct mapping of positive cores to specific anatomical regions of the prostate, information that carries direct relevance to subsequent surgical or focal therapy planning.
In patients with suspicious lesions identified on pre-biopsy multiparametric MRI, additional targeted cores are obtained from these regions using either cognitive registration — in which the operator mentally integrates the MRI findings with the real-time ultrasound anatomy to direct additional passes — or MRI-ultrasound fusion biopsy technology, in which software-based co-registration of the imported MRI data with the real-time ultrasound image enables automated overlay guidance to the target lesion. The combination of systematic and targeted sampling is increasingly recognized as the optimal approach, as each strategy detects a proportion of clinically significant cancers that the other would miss in isolation.
Throughout the procedure, the probe is repositioned and angulated to optimize access to the prostatic apex, which represents a technically challenging sampling location due to its proximity to the external urethral sphincter and its tendency to be undersampled by posterior-directed biopsy trajectories. On conclusion of the sampling protocol, the transrectal probe is withdrawn carefully, the perianal region is inspected, and the patient is monitored briefly before ambulating. A voiding trial may be conducted prior to discharge in patients at risk of urinary retention.
Post-Procedure Care and Recovery
The majority of patients tolerate TRUS-guided prostate biopsy as a well-managed outpatient procedure and are discharged within one to two hours of completion following a period of observation. Minor post-procedural symptoms are common and expected, and patients are counseled regarding their anticipated course prior to departure. Hematuria — blood in the urine — is the most frequently encountered post-biopsy finding, typically manifesting as pink to red-tinged urine in the immediate post-procedural period and resolving spontaneously within one to three days, though minor intermittent discoloration may persist for up to two weeks in some patients. Hematospermia, the presence of blood in the ejaculate, is nearly universal following prostate biopsy and may persist for several weeks to months without clinical significance; patients require explicit reassurance regarding this expected finding to prevent unnecessary alarm.
Rectal bleeding following withdrawal of the probe and needle passes is usually minor and self-limiting, consisting of small amounts of bright red blood per rectum that resolves within twenty-four to forty-eight hours with conservative management. Patients are instructed to maintain adequate oral hydration to ensure urinary dilution, which facilitates clearance of hematuria and reduces the risk of clot formation within the bladder. Strenuous physical activity, prolonged cycling, and activities that generate significant perineal pressure are restricted for forty-eight to seventy-two hours post-procedure.
Oral antibiotic therapy is continued for a defined post-procedural period in accordance with the institutional prophylaxis protocol, typically for two to three days following the procedure. Patients are provided with clear written and verbal instructions regarding the warning signs of infective complications — including fever above 38.5 degrees Celsius, rigors, urinary frequency and dysuria, perineal pain, difficulty voiding, and systemic malaise — with explicit instruction to seek emergency medical evaluation promptly if these symptoms develop, given the potential for rapid progression to septicemia if infection is not treated expeditiously.
Anticoagulant medications that were withheld prior to the procedure are restarted in accordance with the pre-established bridging plan, typically after twenty-four to forty-eight hours provided there is no evidence of significant ongoing bleeding. Histopathological results are generally available within five to seven working days and are communicated to the patient in a formal consultation setting — ideally a multidisciplinary team-based clinical meeting — in which the implications of the findings are explained and the subsequent management pathway is discussed in detail.
Risks and Complications
TRUS-guided prostate biopsy carries a well-characterized complication profile that, in the context of contemporary prophylaxis strategies and image-guided technique, is manageable in the large majority of patients. Infective complications constitute the most clinically significant risk category. Post-biopsy urinary tract infection and prostatitis, presenting with dysuria, urinary frequency, and perineal discomfort, occur in a minority of patients and typically respond to targeted oral antibiotic therapy. Post-biopsy septicemia — the most feared infectious complication — has increased in incidence over the past two decades in parallel with the global rise in fluoroquinolone-resistant rectal flora and remains the principal driver of post-biopsy hospitalization and, in rare cases, critical illness. It manifests as high-grade fever, rigors, hypotension, and systemic inflammatory response and requires emergency hospital admission with intravenous broad-spectrum antibiotics, fluid resuscitation, and intensive monitoring. The shift toward targeted prophylaxis based on rectal swab culture has demonstrably reduced sepsis rates in centers that have implemented this approach.
Urinary retention following biopsy, attributable to post-procedural prostatic edema and inflammation compounding pre-existing outflow obstruction, occurs predominantly in patients with significant baseline lower urinary tract symptoms and enlarged prostate volumes. It is managed with urethral catheterization, alpha-blocker therapy, and close monitoring for resolution as the procedural inflammatory response subsides. Significant rectal bleeding requiring intervention — including endoscopic or surgical hemostasis — is uncommon but represents a recognized complication, particularly in patients with anorectal vascular pathology or inadequately corrected coagulopathy. Vasovagal episodes, characterized by transient bradycardia, hypotension, pallor, and diaphoresis, may occur during or immediately following the procedure in response to rectal instrumentation or procedural discomfort and are managed with patient reassurance, supine positioning, and intravenous fluid administration if required.
Erectile dysfunction as a consequence of prostate biopsy has been reported in the literature and is postulated to result from direct needle-related trauma to the neurovascular bundles, procedural inflammation, or psychological factors associated with the biopsy experience and its oncological implications. Its true incidence attributable specifically to the biopsy procedure is difficult to isolate from pre-existing sexual dysfunction in an aging population. Rare complications including needle track seeding of malignant cells — a theoretical concern with any percutaneous tumor biopsy — have been described in isolated case reports following TRUS-guided biopsy but are considered exceptionally rare in clinical practice and do not constitute a routine clinical concern sufficient to preclude the procedure.
Clinical Outcomes and Effectiveness
TRUS-guided systematic prostate biopsy achieves a clinically meaningful cancer detection rate in patients presenting with elevated PSA or clinical suspicion, with detection rates reflecting the underlying population risk, PSA level at referral, prior biopsy history, and the sampling protocol employed. The extended twelve-core systematic template consistently demonstrates superior detection rates compared to the historical sextant protocol, attributable to more comprehensive sampling of the peripheral zone and reduced geographic miss of anterolateral and apical lesions.
The integration of pre-biopsy multiparametric MRI into the diagnostic pathway has refined the clinical utility of prostate biopsy substantially. PI-RADS 4 and 5 lesions carry a high positive predictive value for clinically significant prostate cancer — defined as Gleason score seven or above — and targeted biopsy of these lesions demonstrates superior detection of clinically significant disease and reduced detection of low-grade, clinically insignificant cancer compared to systematic sampling alone. Conversely, systematic biopsy continues to detect a proportion of clinically significant anterior and transition zone cancers that evade MRI detection, supporting the continued role of the combined systematic and targeted approach rather than exclusive reliance on MRI-directed targeting.
The Gleason grade and ISUP grade group information provided by the biopsy specimen directly informs risk stratification according to established frameworks — including the National Comprehensive Cancer Network, European Association of Urology, and Cancer of the Prostate Risk Assessment systems — which categorize patients into low, intermediate, and high-risk groups and generate treatment recommendations spanning active surveillance for low-risk disease, curative-intent local therapy for intermediate and high-risk localized disease, and systemic treatment for metastatic presentations. The accuracy of this risk stratification is directly dependent on the representativeness and adequacy of the biopsy sampling, underscoring the clinical imperative of meticulous procedural technique.
Transperineal biopsy — in which the needle is introduced through the perineal skin rather than the rectal wall — has emerged as an important alternative approach with a substantially lower infectious complication rate, attributed to avoidance of rectal mucosal transgression and the associated contamination with fecal flora. Multiple clinical series and a growing randomized evidence base support the infective safety advantage of the transperineal approach, and many high-volume centers have adopted it as the preferred technique, particularly for repeat biopsies in patients with prior infective complications, immunocompromised patients, and those harboring fluoroquinolone-resistant organisms.
Conclusion
TRUS-guided prostate biopsy occupies an irreplaceable position in the urological and oncological diagnostic pathway, providing the histopathological tissue diagnosis that underpins every subsequent management decision in a man with suspected or known prostate cancer. Its technical evolution — from the original sextant protocol to the extended twelve-core systematic template, and increasingly to the integration of multiparametric MRI-directed targeted sampling — reflects a continuous refinement driven by the imperative to maximize clinically significant cancer detection while minimizing the detection and overtreatment of indolent disease. The most pressing contemporary challenge facing the procedure is the management of post-biopsy infection risk in an era of rising antimicrobial resistance, a challenge that the field is actively addressing through targeted prophylaxis strategies and the expanding adoption of the transperineal approach. When performed within a structured multidisciplinary pathway — incorporating PSA assessment, imaging evaluation, optimized antibiotic prophylaxis, and meticulous biopsy technique — TRUS-guided prostate biopsy continues to deliver the diagnostic precision and clinical safety that the accurate management of prostate cancer demands.